Chih-Lung Shen

Title: Chih-Lung Shen: Innovator in Genetic Research

Introduction

Chih-Lung Shen is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of genetic research, particularly in understanding the relationship between HLA alleles and adverse drug reactions. With a total of 2 patents, his work has the potential to impact patient safety and treatment efficacy.

Latest Patents

One of Chih-Lung Shen's latest patents focuses on HLA alleles associated with adverse drug reactions and methods for detecting such alleles. This invention relates to a method of determining the presence of specific HLA alleles, such as HLA-B*1502 or HLA-B*5801, and includes a kit for carrying out this method. Additionally, it discloses a method for assessing whether a patient is at risk for developing adverse drug reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome, based on the presence or absence of genetic markers like HLA-B*1502, HLA-B*5801, or HLA-B*4601.

Career Highlights

Chih-Lung Shen has worked with notable organizations, including Academia Sinica and Pharmigene, Inc. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Yuan-Tsong Chen and Shuen-Iu Hung. Their collaborative efforts have further advanced the understanding of genetic markers and their implications in medicine.

Conclusion

Chih-Lung Shen's innovative work in genetic research highlights the importance of understanding HLA alleles in relation to drug reactions. His contributions are paving the way for safer medical practices and improved patient outcomes.